Institutional Clinical and Translational Science Award

机构临床和转化科学奖

基本信息

批准号：
10426378
负责人：
GARRET A FITZGERALD
金额：
$ 1026.02万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10426378
关键词：
Academia Address Adherence Adult Antihypertensive Agents Area Biological Models Cell model Childhood Circadian Dysregulation Clinical Clinical Research Clinical Sciences Clinical and Translational Science Awards Communities Complex Development Disadvantaged Discipline Disease Dose Drug Exposure Educational process of instructing Faculty First Independent Research Support and Transition Awards Fostering Fruit Functional disorder Funding Genomic medicine Goals Growth Health system Home Human Incentives Industry Institutes Institution Intensive Care Intervention Trial Leadership Life Lipids London Measures Messenger RNA Mission Modeling Pediatric Hospitals Pennsylvania Persons Pharmaceutical Preparations Pharmacologic Substance Phenotype Philadelphia Physiological Physiology Pilot Projects Price Private Sector Randomized Research Research Personnel Resources Rural Community Schools Science Series Sickle Cell Anemia Testing The Wistar Institute Therapeutic Time Translating Translational Research United States National Institutes of Health Universities Urban Community Validation Vision cardiovascular risk factor clinical implementation clinical investigation college drug action implementation barriers implementation science improved improved outcome medical schools novel novel therapeutics phenomics pre-clinical precision medicine programs recruit response success translational medicine translational therapeutics uptake

项目摘要

Contact PD/PI: FITZGERALD, GARRET A OVERALL ABSTRACT/SUMMARY The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade and a half the objectives of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period. Project Summary/Abstract Page 136 Contact PD/PI: FITZGERALD, GARRET A OVERALL NARRATIVE The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people.

联系人 PD/PI：FITZGERALD、GARRET A 全面的摘要/总结转化医学和治疗研究所是 CTSA 的学术所在地佩恩。在过去的十五年里，ITMAT 的目标一直是并且仍然是 (i) 增加能够在证明之间进行研究的调查人员数量细胞和模型系统中的概念以及（ii）阐明人类生理学机制，通过对少数人进行强烈的表型分析来确定疾病或药物作用。两人我们的 CTSA 的首要任务是培育转化疗法领域并弥合从儿科到成人的划分跨越了整个临床和转化科学领域。这部分描述了这些优先事项如何影响该 CTSA 中心的发展并概述我们对未来资助期的计划。项目总结/摘要第 136 页联系人 PD/PI：FITZGERALD、GARRET A 全面的叙述转化医学和治疗研究所是 CTSA 的学术所在地佩恩。在过去十年中，ITMAT 的具体目标始终是 (i) 提高能够在细胞概念验证之间进行研究的研究人员数量和模型系统以及（ii）阐明人类生理学、疾病或通过在少数人群中进行强烈的表型分析来确定药物作用。